Open an account

Fennec Pharmaceuticals

FENC · NASDAQ

$10.46+$0.19 (+1.85%)TodayMarket closed ·
Prev close $10.27

About FENC

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Employees
36
Headquarters
RESEARCH TRIANGLE PARK, North Carolina
Listed
Jun 5, 2001
Sector
Health Care
Industry
Biotechnology
Website
fennecpharma.com

FENC key statistics

Market cap
366.80M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
125.56K
Volume
71.00K
Open price
$10.30
High today
$10.73
Low today
$10.12
52 Week high
$13.25
52 Week low
$5.65

Fennec Pharmaceuticals (FENC) at a glance

As of Oct 20, 2026, Fennec Pharmaceuticals (FENC) shares are priced at $10.46, giving the company a market cap of 366.80M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $10.12 and $10.73. The current price is 3.4% above the day's low and 2.5% below its high.

Volume so far is 71.00K shares, below the average of 125.56K shares a day.

Over the past year Fennec Pharmaceuticals has ranged from $5.65 to $13.25, and now sits 63% of the way up that range.

Fennec Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.05 per share against an estimate of $0.01.

The average analyst price target is $18.02, 72.3% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $18.02
Low
$16.16
Now
$10.46
High
$21.00

FENC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 170.4% on average.

  1. Q3 FY24: reported -$0.21 per share against an estimate of -$0.0918
  2. Q4 FY24: reported -$0.06 per share against an estimate of $0.1693
  3. Q1 FY25: reported -$0.04 per share against an estimate of -$0.0906
  4. Q2 FY25: reported -$0.11 per share against an estimate of -$0.0367
  5. Q3 FY25: reported -$0.02 per share against an estimate of -$0.0218
  6. Q4 FY25: reported -$0.10 per share against an estimate of $0.0357
  7. Q1 FY26: reported $0.01 per share against an estimate of -$0.0085
  8. Q2 FY26: reported $0.05 per share against an estimate of $0.01

FENC news

  • Press releaseGlobe Newswire

    Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

  • Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript

  • Press releaseGlobe Newswire

    Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

  • Fennec Pharma Initiates Investigator-Sponsored Study By University Of Arizona Cancer Center To Evaluate Use Of PEDMARK In Adolescent And Young Adult And Adult Patients With Head And Neck And Testicular Cancers Receiving Cisplatin

  • Press releaseGlobe Newswire

    Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

  • Press releaseGlobe Newswire

    Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

Similar companies

Companies in the same industry as Fennec Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.